3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
9
Neoplasms
4
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Trabectedin
4
Doxorubicin
4
toripalimab
2
brigimadlin
2
belinostat
2
Fulvestrant
2
Dexamethasone
2
tanespimycin
1
soblidotin
1
siremadlin
1
selinexor
1
ridaforolimus
1
ribociclib
1
pembrolizumab
1
olaratumab
1
milademetan
1
enzalutamide
1
cemiplimab
1
atezolizumab
1
TTI-621
1
Sugars
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Letrozole
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liposarcoma
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts